⚠ LIVE — European Consumer Safety Watch 💊 Etichetta canale medico: 18 negli ultimi 7 giorni 🍎 Canale alimentare: 180 negli ultimi 7 giorni 🧸 Canale: prodotti: 48 negli ultimi 7 giorni 🟢 Monitoraggio: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Ultimo recupero: 3 ore fa ⚠ LIVE — European Consumer Safety Watch 💊 Etichetta canale medico: 18 negli ultimi 7 giorni 🍎 Canale alimentare: 180 negli ultimi 7 giorni 🧸 Canale: prodotti: 48 negli ultimi 7 giorni 🟢 Monitoraggio: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Ultimo recupero: 3 ore fa
🛡️ EUSW
🇮🇹
💊

Exjade

deferasirox
Talassemia beta; Sovraccarico di ferro
✅ Autorizzato
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.

A cosa serve

Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older. Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged two to five years; in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged two years and older; in patients with other anaemias aged two years and older. Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.

⚠️ Sicurezza del paziente

No

⚠️ Aggregiamo avvisi ufficiali. Non forniamo consulenze mediche. Per decisioni mediche o legali, consulta l'ente di riferimento e un professionista qualificato.